"BofA upgraded HIMS from Underperform to Neutral, raising its price target from $12.50 to $23. The firm cited the dismissal of Novo Nordisk's lawsuit as a clear positive, removing a significant legal cloud that had weighed on the stock. BofA is staying below Street consensus on 2026-2027 revenue estimates, signaling the upgrade reflects reduced downside rather than a conviction call on growth."
"Deutsche Bank upgraded Teladoc from Hold to Buy with a $11 price target, a meaningful premium to its current price. The firm's thesis rests on three pillars: compelling valuation at current levels, a credible longer-term growth plan for the BetterHelp mental health segment, and an illustrated exit path for that business supported by comparable transaction data."
"Across all three, analysts are pointing to reduced uncertainty rather than accelerating fundamentals as the core thesis."
Hims & Hers Health, Teladoc Health, and Alector each received analyst upgrades this week based on strategic developments that reduce investment risk. Hims benefited from resolving its legal dispute with Novo Nordisk through a distribution partnership, with BofA upgrading to Neutral and Deutsche Bank raising its price target. Teladoc earned a Buy rating from Deutsche Bank on improved valuation and a clearer strategic direction for its BetterHelp segment, supported by stable growth in its Integrated Care business. Alector was upgraded to Buy by BTIG following a repositioning of its blood-brain barrier platform after a trial setback. Across all three companies, analysts emphasize reduced downside risk and strategic clarity rather than accelerating business growth as the primary investment thesis.
Read at 24/7 Wall St.
Unable to calculate read time
Collection
[
|
...
]